Your Search Returned 35 tagged news reports
Vivus Inc.'s biggest shareholder said Tuesday it is suing the obesity drug maker as it continues to fight for greater control of the company. First Manhattan Co., which as a 9.9-percent stake in Vivus, filed a lawsuit aiming to stop the drug maker
Obesity drugmaker Vivus Inc on Tuesday said its biggest investor , First Manhattan Co , has been offering only "uncertainty and delay" in its efforts to shake up the company's board of directors. "FMC's 'plan' - to the extent they have one - appears
Vivus Inc 's largest shareholder, First Manhattan Co , said on Friday proxy advisory firm Institutional Shareholder Services recommended three of the nine directors the shareholder had proposed for nomination to the drugmaker's board. Another
A proxy war with its top shareholder is building up the pressure on Vivus Inc to quickly ramp up the sales of its diet drug, Qsymia , as skepticism grows among investors and analysts about the medicine's potential. First Manhattan Co, with a 9.9
Monday were AXT Inc, MediciNova, Amyris, Universal Display Corp and TGC Industries Inc.
The higher costs of selling Qsymia, along with associated general and administrative expenses, pushed up the company's loss. This latest loss pushed Vivus' accumulated deficit -- how much money it has lost or written off since it started -- to $486,
Inc, Arena Pharmaceuticals, and the Weight-loss Craze Meena is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. According to a Centers for Disease Control study earlier
Food and Drug Administration in July is now available for obese and at-risk overweight patients. The oral medication Qsymia can only be obtained with a doctor's prescription. Qsymia (pronounced kyoo-SIM-ee-uh) is the second diet drug approved this
Former Bergen Co. drug marker lands obesity drug contract * Parsippany -based PDI will market Vivus' obesity medication. A New Jersey company that markets drugs to the physicians who prescribe them stands to benefit from the government's approval
The Food and Drug Administration on Tuesday approved a new weight loss drug from Vivus Inc. that many doctors consider the most effective therapy in a new generation of anti-obesity pills designed to help patients safely shed pounds.